Linzess sales strength, apraglutide Phase III catalyst, FY2026 guidance and $5.37 target—read now for key upside drivers.

In goods- and manufacturing-focused industries, the most valuable intellectual property is frequently not the product design or formulation offered to the public, but rather the process behind it.

GLP-1 therapies created a consumer-driven market for pharmaceuticals that pairs digital access, partnerships, and retention ...

Netlist (OTCMKTS:NLST) reported record quarterly revenue for the first quarter of 2026, citing strong demand for memory ...